Fagron N.V.
A global pharmaceutical compounding company focused on personalized medicine.
FAGR | BR
Overview
Corporate Details
- ISIN(s):
- BE0003874915
- LEI:
- 549300TRKRUFK2RRG779
- Country:
- Belgium
- Address:
- Venecoweg 20A, 9810 Nazareth
- Website:
- https://fagron.com/
- Sector:
- Manufacturing
Description
Fagron N.V. is a global company active in pharmaceutical compounding, focusing on the delivery of personalized medicine. The company optimizes and innovates compounding to widen the therapeutic options for prescribers worldwide. Fagron develops, markets, and distributes pharmaceutical raw materials, equipment, and specially formulated vehicles and bases, such as the Pentravan® transdermal base and the SyrSpend® range of oral suspending vehicles. Its primary customers are hospitals, pharmacies, and clinics. The company also operates in the field of genomics to further support personalized healthcare solutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2014-12-11 00:00 |
Arseus announces successful progress in the US compounding market
|
English | DOC • 111.3 KB | ||
| 2014-12-11 00:00 |
Arseus maakt positieve ontwikkelingen bekend in de US compounding markt
|
Dutch | DOC • 113.9 KB | ||
| 2014-11-11 00:00 |
ENG Convocation EGM 12 December 2014.pdf
|
English | DOC • 55.2 KB | ||
| 2014-11-11 00:00 |
NE Volmacht BAVA 12 december 2014.pdf
|
Dutch | DOC • 48.3 KB | ||
| 2014-11-11 00:00 |
ENG Achtergrondinformatie EGM 12 December 2014.pdf
|
English | DOC • 14.2 KB | ||
| 2014-11-11 00:00 |
NE Oproeping BAVA 12 december 2014.pdf
|
Dutch | DOC • 51.4 KB | ||
| 2014-11-11 00:00 |
ENG Proxy EGM 12 December 2014.pdf
|
English | DOC • 48.4 KB | ||
| 2014-11-11 00:00 |
NE Achtergrondinformatie BAVA 12 December 2014.pdf
|
Dutch | DOC • 14.4 KB | ||
| 2014-11-11 00:00 |
20141111 Final Convocation EGM 12 Dec Arseus.pdf
|
English | DOC • 197.5 KB | ||
| 2014-11-11 00:00 |
20141111 Final Oproeping BAVA 12 december 2014 Arseus.pdf
|
Dutch | DOC • 199.8 KB | ||
| 2014-10-08 08:45 |
Arseus: YEAR TO DATE GROWTH OF 34.4% OF WHICH 12.9% ORGANIC
|
English | DOC • 198.3 KB | ||
| 2014-10-08 08:45 |
Arseus: YEAR TO DATE GROWTH OF 34.4% OF WHICH 12.9% ORGANIC
|
English | DOC • 195.9 KB | ||
| 2014-10-08 00:00 |
Year to date growth 34.4% of which 12.9% organic
|
English | DOC • 198.3 KB | ||
| 2014-10-08 00:00 |
Groei 34,4% year to date waarvan 12,9% organisch
|
Dutch | DOC • 195.9 KB | ||
| 2014-09-30 08:11 |
ARSEUS: PUBLICATION OF GUARANTOR LIST AND COMPLIANCE CERTIFICATE
|
English | DOC • 126.1 KB |
Automate Your Workflow. Get a real-time feed of all Fagron N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Fagron N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Fagron N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-23 | Pulido Andrew | Executive member | Sell | 85,000 | 1,803,351.50 EUR |
| 2025-05-22 | Pulido Andrew | Executive member | Buy | 85,000 | 1,617,550.00 EUR |
| 2025-05-02 | De Jong Cornelia Neeltje | Board | Sell | 12,689 | 263,834.55 EUR |
| 2025-04-30 | De Jong Cornelia Neeltje | Board | Sell | 229 | 4,660.15 EUR |
| 2025-04-29 | De Jong Cornelia Neeltje | Board | Sell | 10,000 | 201,500.00 EUR |
| 2025-03-28 | J. Verlinden | Other | Buy | 24,551 | 453,702.48 EUR |
| 2025-03-28 | J. Verlinden | Other | Sell | 17,930 | 344,047.56 EUR |
| 2025-03-27 | Padilla Rafael | Board | Buy | 78,469 | 1,450,107.12 EUR |
| 2025-03-27 | De Jong Cornelia Neeltje | Board | Buy | 45,418 | 839,324.64 EUR |
| 2025-02-21 | Bakker Vera | Executive member | Buy | 773 | 15,000.00 EUR |
Peer Companies
